The findings from the OI trials could have beneficial side effects for the management of ovarian cancer patients as well who are mostly menopausal and over time suffer significant bone mass loss [258].Trabedersen (AP12009 or OT-101) has also emerged as an alternative strategy, which is an antisense approach targeting TGFβ specifically and has shown significant promise in pre-clinical ovarian cancer models [259]. This evidence concerns the gene TGFB1 and ovarian carcinoma.